Sign In
Buy NBIX
Neurocrine Biosciences Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $1.22 |
| EPS actual | $1.94 |
| EPS Surprise | 59.02% |
| Revenue estimate | 768.251M |
| Revenue actual | 814.5M |
| Revenue Surprise | 6.02% |
| Release date | Feb 11, 2026 |
| EPS estimate | $1.80 |
| EPS actual | $1.88 |
| EPS Surprise | 4.44% |
| Revenue estimate | 790.499M |
| Revenue actual | 805.5M |
| Revenue Surprise | 1.90% |
| Release date | Oct 28, 2025 |
| EPS estimate | $1.58 |
| EPS actual | $2.04 |
| EPS Surprise | 29.11% |
| Revenue estimate | 806.802M |
| Revenue actual | 794.9M |
| Revenue Surprise | -1.48% |
| Release date | Jul 30, 2025 |
| EPS estimate | $0.98 |
| EPS actual | $1.06 |
| EPS Surprise | 8.16% |
| Revenue estimate | 746.41M |
| Revenue actual | 687.5M |
| Revenue Surprise | -7.89% |
Last 4 Quarters for Neurocrine Biosciences
Below you can see how NBIX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 30, 2025 |
| Price on release | $136.76 |
| EPS estimate | $0.98 |
| EPS actual | $1.06 |
| EPS surprise | 8.16% |
| Date | Price |
|---|---|
| Jul 24, 2025 | $131.64 |
| Jul 25, 2025 | $132.14 |
| Jul 28, 2025 | $133.71 |
| Jul 29, 2025 | $134.19 |
| Jul 30, 2025 | $136.76 |
| Jul 31, 2025 | $128.23 |
| Aug 01, 2025 | $128.91 |
| Aug 04, 2025 | $128.04 |
| Aug 05, 2025 | $128.39 |
| 4 days before | 3.89% |
| 4 days after | -6.12% |
| On release day | -6.24% |
| Change in period | -2.47% |
| Release date | Oct 28, 2025 |
| Price on release | $147.38 |
| EPS estimate | $1.58 |
| EPS actual | $2.04 |
| EPS surprise | 29.11% |
| Date | Price |
|---|---|
| Oct 22, 2025 | $141.47 |
| Oct 23, 2025 | $143.67 |
| Oct 24, 2025 | $144.00 |
| Oct 27, 2025 | $148.94 |
| Oct 28, 2025 | $147.38 |
| Oct 29, 2025 | $138.02 |
| Oct 30, 2025 | $138.04 |
| Oct 31, 2025 | $143.21 |
| Nov 03, 2025 | $141.96 |
| 4 days before | 4.18% |
| 4 days after | -3.68% |
| On release day | -6.35% |
| Change in period | 0.346% |
| Release date | Feb 11, 2026 |
| Price on release | $137.44 |
| EPS estimate | $1.80 |
| EPS actual | $1.88 |
| EPS surprise | 4.44% |
| Date | Price |
|---|---|
| Feb 05, 2026 | $137.93 |
| Feb 06, 2026 | $141.20 |
| Feb 09, 2026 | $139.56 |
| Feb 10, 2026 | $137.65 |
| Feb 11, 2026 | $137.44 |
| Feb 12, 2026 | $123.10 |
| Feb 13, 2026 | $124.00 |
| Feb 17, 2026 | $127.76 |
| Feb 18, 2026 | $128.38 |
| 4 days before | -0.355% |
| 4 days after | -6.59% |
| On release day | -10.43% |
| Change in period | -6.92% |
| Release date | May 05, 2026 |
| Price on release | $135.06 |
| EPS estimate | $1.22 |
| EPS actual | $1.94 |
| EPS surprise | 59.02% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $131.23 |
| Apr 30, 2026 | $131.67 |
| May 01, 2026 | $131.78 |
| May 04, 2026 | $134.07 |
| May 05, 2026 | $135.06 |
| May 06, 2026 | $147.02 |
| May 07, 2026 | $149.59 |
| May 08, 2026 | $152.25 |
| May 11, 2026 | $150.59 |
| 4 days before | 2.92% |
| 4 days after | 11.50% |
| On release day | 8.86% |
| Change in period | 14.75% |
Neurocrine Biosciences Earnings Call Transcript Summary of Q1 2026
Neurocrine reported a strong start to 2026 with quarterly net product sales topping $800 million (44% YoY growth), driven primarily by INGREZZA (Q1 sales $657M, +20% YoY) and growing CRENESSITY revenue ($153M in Q1, annualizing >$600M). INGREZZA guidance was reaffirmed at $2.7B–$2.8B for 2026. The pending acquisition of Soleno Therapeutics (VYKAT XR) remains on track to close in Q2 and is expected to broaden the company's rare-disease franchise (Prader-Willi Syndrome) following integration. Financially, Neurocrine generated approximately $200M of net income in Q1 and emphasized that commercial cash flows from INGREZZA and CRENESSITY will fund ongoing R&D and BD priorities. R&D momentum is high: the company plans 6 new Phase I and 4 new Phase II starts in 2026 and highlighted key upcoming catalysts — notably topline Phase III readouts for osavampator in major depressive disorder and an initial Phase III direclidine readout in schizophrenia in 2027, plus NBIP-2118 obesity data expected in 2027. CRENESSITY commercialization is progressing ahead of initial expectations with steady new patient starts, high persistency, favorable reimbursement, and broadening prescriber adoption (pediatrics, adult endocrinologists, CAH centers). Management emphasized continued investment in commercial expansion and a disciplined capital allocation framework: grow revenue, advance the pipeline, and pursue strategic BD.
